Elucidating the specific pharmacological mechanism of motion (MOA) of In a natural way occurring compounds is often tough. Whilst Tarselli et al. (60) made the first de novo artificial pathway to conolidine and showcased this The natural way developing compound successfully suppresses responses to both chemically induced and inflammation-derived pa